FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056569366> ?p ?o ?g. }

• W2056569366 endingPage "384" @default.
• W2056569366 startingPage "379" @default.
• W2056569366 abstract "In order to assess the androgenic activity of synthetic progestins currently used as antiandrogens for the treatment of prostate cancer in men, the effect of a series of these compounds has been measured following 14 days of treatment of adult castrated rats on specific and sensitive parameters of androgenic activity, namely ventral prostate weight and prostatic ornithine decarboxylase (ODC) activity. Medroxyprogesterone acetate (MPA) is almost equipotent with 5 alpha-dihydrotestosterone (DHT), a 49% increase in prostatic weight being observed at the low dose of 0.15 mg, twice daily (P less than 0.01). Megestrol acetate (Megace), chlormadinone acetate (CMA) and spironolactone were less potent but caused a 36-59% increase in prostatic weight at the highest dose used, namely 10 mg. At the 5 mg dose, cyproterone acetate (CPA) caused a 75% increase in prostatic weight. The androgenic activity of the compounds is even more clearly illustrated by their marked stimulatory effect on prostatic ornithine decarboxylase (ODC) activity. MPA, at the low dose of 0.15 mg, caused a 20-fold increase (relative to the effect of placebo) in the activity of the enzyme while the same dose of DHT caused a 15-fold stimulation of enzymatic activity. At the 10 mg dose, megestrol acetate, CMA and spironolactone caused 13.1, 11.8 and 8.6-fold stimulations of ODC activity, respectively. Flutamide, on the other hand, had no stimulatory effect on either ventral prostate weight or prostatic ODC activity. In agreement with glucocorticoid activity, MPA, megestrol acetate and CMA caused a marked inhibition (45-64%) of adrenal weight. The present data show that MPA is a highly potent androgen while megestrol acetate, CMA, CPA and spironolactone have lower but significant androgenic activity on all the parameters measured. It should be added that MPA, megestrol acetate and CMA are completely devoid of antiandrogenic activity while spironolactone shows weak antiandrogen action and CPA is a mixed agonist-antagonist. Flutamide, the compound used as reference, is the only compound devoid of any androgenic action and is thus acting as a pure antiandrogen on both ventral prostate weight and prostatic ODC activity. The present data have major implications for the choice of drug to be used for the treatment of androgen-sensitive diseases, especially prostate cancer. As shown by the present data, the synthetic progestins so-far available all possess variable levels of androgenic activity and are thus not recommended for the treatment of prostate cancer." @default.
• W2056569366 created "2016-06-24" @default.
• W2056569366 creator A5003484727 @default.
• W2056569366 creator A5023570210 @default.
• W2056569366 creator A5037375384 @default.
• W2056569366 creator A5065560889 @default.
• W2056569366 creator A5077864181 @default.
• W2056569366 date "1987-10-01" @default.
• W2056569366 modified "2023-10-03" @default.
• W2056569366 title "Analysis of the androgenic activity of synthetic “progestins” currently used for the treatment of prostate cancer" @default.
• W2056569366 cites W1894618651 @default.
• W2056569366 cites W1965037602 @default.
• W2056569366 cites W1971263167 @default.
• W2056569366 cites W1978612689 @default.
• W2056569366 cites W1981136773 @default.
• W2056569366 cites W1989712846 @default.
• W2056569366 cites W1994047807 @default.
• W2056569366 cites W1994174350 @default.
• W2056569366 cites W1997822677 @default.
• W2056569366 cites W1999481935 @default.
• W2056569366 cites W2004398919 @default.
• W2056569366 cites W2006155322 @default.
• W2056569366 cites W2009498181 @default.
• W2056569366 cites W2012104408 @default.
• W2056569366 cites W2013905345 @default.
• W2056569366 cites W2033910940 @default.
• W2056569366 cites W2053535796 @default.
• W2056569366 cites W2054493005 @default.
• W2056569366 cites W2057880686 @default.
• W2056569366 cites W2071708635 @default.
• W2056569366 cites W2072685254 @default.
• W2056569366 cites W2079083023 @default.
• W2056569366 cites W2085131815 @default.
• W2056569366 cites W2087861136 @default.
• W2056569366 cites W2281124822 @default.
• W2056569366 cites W2308091732 @default.
• W2056569366 cites W2329442555 @default.
• W2056569366 cites W2407124432 @default.
• W2056569366 cites W2415145478 @default.
• W2056569366 cites W4230006861 @default.
• W2056569366 cites W4293247451 @default.
• W2056569366 doi "https://doi.org/10.1016/0022-4731(87)91054-5" @default.
• W2056569366 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2444770" @default.
• W2056569366 hasPublicationYear "1987" @default.
• W2056569366 type Work @default.
• W2056569366 sameAs 2056569366 @default.
• W2056569366 citedByCount "85" @default.
• W2056569366 countsByYear W20565693662012 @default.
• W2056569366 countsByYear W20565693662014 @default.
• W2056569366 countsByYear W20565693662015 @default.
• W2056569366 countsByYear W20565693662016 @default.
• W2056569366 countsByYear W20565693662017 @default.
• W2056569366 countsByYear W20565693662018 @default.
• W2056569366 countsByYear W20565693662019 @default.
• W2056569366 crossrefType "journal-article" @default.
• W2056569366 hasAuthorship W2056569366A5003484727 @default.
• W2056569366 hasAuthorship W2056569366A5023570210 @default.
• W2056569366 hasAuthorship W2056569366A5037375384 @default.
• W2056569366 hasAuthorship W2056569366A5065560889 @default.
• W2056569366 hasAuthorship W2056569366A5077864181 @default.
• W2056569366 hasConcept C121289238 @default.
• W2056569366 hasConcept C121608353 @default.
• W2056569366 hasConcept C126322002 @default.
• W2056569366 hasConcept C134018914 @default.
• W2056569366 hasConcept C181199279 @default.
• W2056569366 hasConcept C185592680 @default.
• W2056569366 hasConcept C2776235491 @default.
• W2056569366 hasConcept C2776306185 @default.
• W2056569366 hasConcept C2776306840 @default.
• W2056569366 hasConcept C2777155358 @default.
• W2056569366 hasConcept C2777911890 @default.
• W2056569366 hasConcept C2778313021 @default.
• W2056569366 hasConcept C2779320873 @default.
• W2056569366 hasConcept C2779322244 @default.
• W2056569366 hasConcept C2779881493 @default.
• W2056569366 hasConcept C2780146029 @default.
• W2056569366 hasConcept C2780192828 @default.
• W2056569366 hasConcept C2780723184 @default.
• W2056569366 hasConcept C2908647359 @default.
• W2056569366 hasConcept C2910016293 @default.
• W2056569366 hasConcept C2986740045 @default.
• W2056569366 hasConcept C55493867 @default.
• W2056569366 hasConcept C61367390 @default.
• W2056569366 hasConcept C71315377 @default.
• W2056569366 hasConcept C71924100 @default.
• W2056569366 hasConcept C99454951 @default.
• W2056569366 hasConceptScore W2056569366C121289238 @default.
• W2056569366 hasConceptScore W2056569366C121608353 @default.
• W2056569366 hasConceptScore W2056569366C126322002 @default.
• W2056569366 hasConceptScore W2056569366C134018914 @default.
• W2056569366 hasConceptScore W2056569366C181199279 @default.
• W2056569366 hasConceptScore W2056569366C185592680 @default.
• W2056569366 hasConceptScore W2056569366C2776235491 @default.
• W2056569366 hasConceptScore W2056569366C2776306185 @default.
• W2056569366 hasConceptScore W2056569366C2776306840 @default.
• W2056569366 hasConceptScore W2056569366C2777155358 @default.
• W2056569366 hasConceptScore W2056569366C2777911890 @default.
• W2056569366 hasConceptScore W2056569366C2778313021 @default.

• next